Featured Research

from universities, journals, and other organizations

Botulinum toxin A creates muscle weakness and atrophy following long term use, study suggests

Date:
December 2, 2010
Source:
University of Calgary
Summary:
A new study found animals injected with Botulinum toxin A experienced muscle weakness and atrophy far from the site of injection. The research raises some important questions about the long-term therapeutic use of Botox.

A new study by researchers at the Faculty of Kinesiology, University of Calgary, is raising questions about the therapeutic use of botulinum toxin A.

The study found that animals injected with Clostridium Botulinum type A neurotoxin complex (BOTOX, Allergan, Inc., Toronto, Ontario, Canada) experienced muscle weakness in muscles throughout the body, even though they were far removed from the injection site. The study also found that repeated injection induced muscle atrophy and loss of contractile tissue in the limb that was not injected with the Toxin.

"We were surprised by the degree of muscle loss and atrophy in the limb that was not injected with the Botulinum toxin," says Rafael Fortuna the lead author of the paper will soon be published in The Journal of Biomechanics, "I think it's fair to say that the paper raises some important questions about the long-term therapeutic use of Botox, especially with children and adolescents."

The study used dosages that approximated therapeutic doses used to treat conditions like cerebral palsy where muscle contraction can't be controlled resulting in muscle dystonia and spasticity. The study follows previous research in Dr. Walter Herzog's lab, which found that Botulinum toxin A, easily crosses the muscle membrane barrier, resulting in muscles weakness in the surrounding (non-injected) muscles.

This study shows, for the first time, that over time Botulinum toxin A use also results in muscle weakness, atrophy and loss of contractile tissue in non-injected muscles far-removed from the injection site."It may be that the benefits of using Botox for these kinds of therapeutic, medical uses, outweighs these potential long-term consequences," says Dr. Herzog, "however I think this study raises some important issues that need to be followed to ensure the best possible outcomes for patients, in the long term."

Botulinum Toxin A is also used as a cosmetic treatment, where the drug paralyzes small muscles in the face to reduce the appearance of wrinkles.

Herzog notes that while this study was looking at larger doses, the results should be valid for any application of the drug.


Story Source:

The above story is based on materials provided by University of Calgary. Note: Materials may be edited for content and length.


Cite This Page:

University of Calgary. "Botulinum toxin A creates muscle weakness and atrophy following long term use, study suggests." ScienceDaily. ScienceDaily, 2 December 2010. <www.sciencedaily.com/releases/2010/12/101202124248.htm>.
University of Calgary. (2010, December 2). Botulinum toxin A creates muscle weakness and atrophy following long term use, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/12/101202124248.htm
University of Calgary. "Botulinum toxin A creates muscle weakness and atrophy following long term use, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/12/101202124248.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins